Compare ANL & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANL | MMD |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 285.6M |
| IPO Year | 2022 | N/A |
| Metric | ANL | MMD |
|---|---|---|
| Price | $7.10 | $14.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 196.2K | 44.4K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.88% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $14.00 |
| 52 Week High | $12.09 | $15.82 |
| Indicator | ANL | MMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 27.45 |
| Support Level | $1.36 | $14.40 |
| Resistance Level | $9.98 | $15.17 |
| Average True Range (ATR) | 0.89 | 0.21 |
| MACD | -0.33 | -0.05 |
| Stochastic Oscillator | 13.03 | 5.45 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.